Literature DB >> 2649866

The neonatal human's immune response to herpes simplex virus infection: a critical review.

S Kohl1.   

Abstract

The neonate has a variety of quantitative defects in its immune response in elements of both the early containment phase and the later curative phase to HSV infection (Table 2). It is likely that the combination of these defects, and possibly others yet to be delineated (IL-2 response, T cell cytotoxicity response, etc.), account for dissemination or for locally progressive illness in newborn infants. It is unlikely that all these defects can be reconstituted by current available modalities (immunoglobulin, interferons, interleukins). One would hope that improving one or a few of these mechanisms may tilt the balance away from dissemination or central nervous system disease and allow the neonate to mature immunologically.

Entities:  

Mesh:

Year:  1989        PMID: 2649866

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  14 in total

1.  Recombinant interleukin-1 alpha, interleukin-2 and M-CSF-1 enhance the survival of newborn C57BL/6 mice inoculated intraperitoneally with a lethal dose of herpes simplex virus-1.

Authors:  C Berkowitz; Y Becker
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  A randomized placebo-controlled trial of massage therapy on the immune system of preterm infants.

Authors:  Jocelyn Y Ang; Jorge L Lua; Ambika Mathur; Ronald Thomas; Basim I Asmar; Sureyya Savasan; Steven Buck; Michael Long; Seetha Shankaran
Journal:  Pediatrics       Date:  2012-11-12       Impact factor: 7.124

3.  Immunobiology of herpes simplex virus and cytomegalovirus infections of the fetus and newborn.

Authors:  William J Muller; Cheryl A Jones; David M Koelle
Journal:  Curr Immunol Rev       Date:  2010

4.  Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.

Authors:  S Kohl; N C Strynadka; R S Hodges; L Pereira
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

5.  Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice.

Authors:  C Berkowitz; M Moyal; A Rösen-Wolff; G Darai; Y Becker
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

6.  The herpes-specific immune response of individuals with herpes-associated erythema multiforme compared with that of individuals with recurrent herpes labialis.

Authors:  S L Brice; S S Stockert; J D Bunker; D Bloomfield; J C Huff; D A Norris; W L Weston
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

7.  Herpes simplex virus-2 (HSV-2) type-specific antibody correlates of protection in infants exposed to HSV-2 at birth.

Authors:  R L Ashley; J Dalessio; S Burchett; Z Brown; S Berry; K Mohan; L Corey
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  Detection of IL-1 beta, TNF-alpha, and IL-6 gene transcription by the polymerase chain reaction in keratinocytes, Langerhans cells and peritoneal exudate cells during infection with herpes simplex virus-1.

Authors:  E Sprecher; Y Becker
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

9.  Transplacental transfer and subsequent neonate utilization of herpes simplex virus-specific immunity are resilient to acute maternal stress.

Authors:  Jodi L Yorty; Robert H Bonneau
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Dysregulated expression of IFN-gamma and IL-10 and impaired IFN-gamma-mediated responses at different disease stages in patients with genital herpes simplex virus-2 infection.

Authors:  R Singh; A Kumar; W D Creery; M Ruben; A Giulivi; F Diaz-Mitoma
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.